Compare iShares MSCI India ETF (INDA) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI India ETF vs McKesson Corporation — how do they compare? iShares MSCI India ETF trades at $48.48, while McKesson Corporation trades at $832.45 (market cap $97.35B). The key difference: McKesson Corporation pays a 0.39% dividend while iShares MSCI India ETF pays none, and McKesson Corporation is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals.
| INDA | MCK | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $55.29 | $995.69 |
52-Week Low | $45.42 | $659.01 |
Market Cap | — | $97.35B |
Enterprise Value | — | $101.98B |
Dividend Yield | — | 0.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDA, the iShares MSCI India ETF, trades at $48.56, down 0.72% on the day. The technical outlook is bearish, with moving averages indicating selling pressure and oscillators neutral. Recent news highlights India's strong economic growth at 7.8% for Q1 2026 (CNBC, 2026-06-05) but notes headwinds including muted IT sector performance and geopolitical risks from the Middle East.
The ETF offers exposure to India's fast-growing economy but faces near-term risks from sector-specific challenges and external volatility. Analyst sentiment is mixed, with some seeing value in the long-term growth story despite recent underperformance versus other emerging markets.
McKesson (MCK) trades at $828.84, down 1.49% on the day, with a bullish technical outlook supported by moving averages and key support at $826. The company shows strong revenue growth, reaching $359.05B in 2025, and has beaten EPS estimates for three consecutive quarters. Analyst sentiment is overwhelmingly positive with 24 buy ratings and a consensus price target of $932.83, indicating 12.5% upside potential.
The outlook for MCK remains favorable due to consistent earnings beats, robust cash flow generation, and leadership in healthcare distribution. Risks include thin profit margins (1.18% net margin) and high liabilities relative to equity. Investors should focus on execution in specialty pharma and oncology services as key growth drivers amid competitive and regulatory pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
